Abstract
Alzheimers disease (AD) is the most common cause of dementia with aging, that is pathologically characterized by senile plaques that contain amyloid-b peptides (Aβ) and neurofibrillary tangles comprised of phosphorylated tau. Genetic and biological studies provide evidence that the production and deposition of Aβ contribute to the etiology of AD. g-Secretase is the pivotal enzyme in generating the C terminus of Aβ, that determines its aggregability and propensity for deposition. Drugs that regulate the production of Aβ by inhibiting g-secretase activity could provide an effective therapeutics for AD, although recent studies suggest that g-secretase plays important roles in novel signaling pathways that play essential roles in embryonic development. This review focuses on recent progresses in the g-secretase biology that shed substantial light on the proteolytic mechanism, regulation and composition of this unusual enzyme. Moreover, we review the recent development of inhibitors and provide a direction for the effective treatment of AD through inhibition of g-secretase activity.
Keywords: Alzheimer's disease, amyloid, γ-secretase, presenilin, aspartic protease, intramembrane proteolysis, protease inhibitor
Current Pharmaceutical Design
Title: γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease
Volume: 12 Issue: 6
Author(s): Taisuke Tomita and Takeshi Iwatsubo
Affiliation:
Keywords: Alzheimer's disease, amyloid, γ-secretase, presenilin, aspartic protease, intramembrane proteolysis, protease inhibitor
Abstract: Alzheimers disease (AD) is the most common cause of dementia with aging, that is pathologically characterized by senile plaques that contain amyloid-b peptides (Aβ) and neurofibrillary tangles comprised of phosphorylated tau. Genetic and biological studies provide evidence that the production and deposition of Aβ contribute to the etiology of AD. g-Secretase is the pivotal enzyme in generating the C terminus of Aβ, that determines its aggregability and propensity for deposition. Drugs that regulate the production of Aβ by inhibiting g-secretase activity could provide an effective therapeutics for AD, although recent studies suggest that g-secretase plays important roles in novel signaling pathways that play essential roles in embryonic development. This review focuses on recent progresses in the g-secretase biology that shed substantial light on the proteolytic mechanism, regulation and composition of this unusual enzyme. Moreover, we review the recent development of inhibitors and provide a direction for the effective treatment of AD through inhibition of g-secretase activity.
Export Options
About this article
Cite this article as:
Tomita Taisuke and Iwatsubo Takeshi, γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474206
DOI https://dx.doi.org/10.2174/138161206775474206 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: Advances in Understanding Alzheimer's Disease, and the Contributions of Current Alzheimer Research: Ten Years on and Beyond
Current Alzheimer Research Herbals and Natural Dietary Supplements in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued) Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Effect of Different Aβ Aggregates as Antigen on the Measure of Naturally Occurring Autoantibodies against Amyloid-β40/42 in IVIG
Current Alzheimer Research Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Current Pharmaceutical Design Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
CNS & Neurological Disorders - Drug Targets The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Chemical Analysis of the Chinese Herbal Medicine Turmeric (Curcuma longa L.)
Current Pharmaceutical Analysis Humanized Mouse Models of HIV-1 Latency
Current HIV Research HIV-1 TAR RNA: The Target of Molecular Interactions Between the Virus and its Host
Current HIV Research Exogenous Progesterone: A Potential Therapeutic Candidate in CNS Injury and Neurodegeneration
Current Medicinal Chemistry The Role of Atropine Eye Drops in Myopia Control
Current Pharmaceutical Design Heightened Attention for Wnt Signaling in Diabetes Mellitus
Current Neurovascular Research Increased Neutrophil-to-lymphocyte Ratios are Associated with Greater Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development?
Current Vascular Pharmacology Microdose Lithium Treatment Stabilized Cognitive Impairment in Patients with Alzheimer’s Disease
Current Alzheimer Research Recent Advances in the Applications of SAMP/RAMP as Chiral Auxiliaries in Asymmetric Synthesis
Current Organic Synthesis Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry Platelets in Atherothrombosis - Diagnostic and Prognostic Value of Platelet Activation in Patients with Atherosclerotic Diseases
Current Vascular Pharmacology